Stay updated with breaking news from Benjamin Ebert. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The four inaugural recipients of the Lubin Family Foundation Scholar Award have been announced by Dana-Farber Cancer Institute and the Richard K. Lubin Family Foundation.
Kungl. Vetenskapsakademien: New knowledge about a cancer pharmaceutical led to the Sjöberg Prize MALMÖ, Sweden, Feb. 15, 2021 /PRNewswire/ -- Benjamin L. Ebert, USA, receives this year's Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer. His discovery of the mechanism that promotes protein breakdown in cancer cells may be vitally important to the future development of new pharmaceuticals. The story of this pharmaceutical begins with a tragedy as, in the 1950s and 1960s, pregnant women with severe morning sickness were...
Benjamin L. Ebert, USA, receives this year's Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer.
Date Time Dana-Farber Medical Oncology Chair receives Sjöberg Prize for cancer research Benjamin Ebert, MD, PhD, Chair of Medical Oncology at Dana-Farber Cancer Institute, George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, and Institute Member of Broad Institute of Harvard and MIT, has been awarded the Sjöberg Prize, an annual international prize in cancer research. The prize was awarded for Dr. Ebert’s discovery of the mode of action of lenalidomide in the treatment of hematological disorders. This is the fifth time that the Sjöberg Prize will ...
CAR T cells are a breakthrough class of effective but often toxic cancer therapies To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug BOSTON - Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but which pose a significant risk of toxic side effects. CAR T cells are immune cells genetically modified ...